World Pharma Today recently spoke with Dr. Thomas Megerian, a physician who has spent three decades in neurodevelopmental medicine. He serves as Clinical Director of the Thompson Autism and Developmental Center at the Children’s Hospital of Orange County and as Chief of the Division of Neurodevelopmental Medicine. In this exclusive feature, Dr. Megerian discusses L-179, the investigational drug he believes could change the trajectory of autism treatment for a meaningful subset of patients, and the challenges that stand between promising Phase 2 data and regulatory approval.
A Career Measured in Hope
Dr. Thomas Megerian does not mince words when describing the state of autism treatment. After 30 years of treating children with neurodevelopmental disabilities, he still remains candid about the emotional toll of the limited progress which has been achieved.
He describes himself as heartbroken by the lack of advancement when it comes to treating the core symptoms of autism. It is a burden which he carries personally, not just professionally. And it is this burden that fuels his determination to bring something meaningful to families who have waited far too long.
His motivation is not abstract but it happens to be rooted in legacy and, of course, measurable impact. He speaks in practical, population-level terms, expressing a desire to leave something behind which goes on to make a meaningful difference. He is also realistic about the scope of what one treatment can achieve, targeting a potential impact range of 20% to 30% of children. For him, that is not a compromise but a meaningful victory in a field where victories have been pretty scarce.
He also acknowledges the fact that he is not keen to be a part of promotional activities, including appearing in videos or public-facing campaigns. Yet he participates because it is essential. Research requires funding. Clinical trials require resources. And without both, the science cannot move forward. His willingness to step into the spotlight is all about ensuring that the work keep taking place.
Understanding L-179’s Place in the Drug Development Pathway
L-179 is an investigational drug that has completed Phase 2 studies. To understand what that means, Dr. Megerian explains the standard phases of drug development.
Phase 1 is typically performed in healthy volunteers in order to determine dosing and safety. Phase 2 is conducted in individuals who have the disease, thereby further refining dosing and safety while also evaluating signals of efficacy. Phase 3 is the pivotal approval-stage trial. If results show both safety and efficacy in improving the intended outcome, regulatory agencies may as well allow the drug to be marketed.
L-179 has completed Phase 2 studies. The team views inferences as promising, forming the basis for moving forward. The immediate program need is explicit and they are looking to have funding to initiate Phase 3.
The name L-179 carries significance beyond a simple designation. It happens to be derived from the New Testament, specifically Luke 1:79, which reads – to shine on those living in darkness, and in the shadow of death, to guide our feet into the path of peace. Dr. Megerian frames this reference as aligned with the drug’s guiding purpose. It is intended to help individuals who feel impaired and not able to completely enjoy life.
Therapeutic Goals and Symptom Targets
Autism is clinically and diagnostically defined through two required core symptom domains. The first is impairment in social communication that interferes with functioning. The second is repetitive and restricted patterns of behaviour.
L-179 is primarily focused on the first domain: strengthening social communication and the ability to socially interact. Dr. Megerian notes there is some indication it may also help with the second domain, involving repetitive and restricted behaviours. However, the central therapeutic aim remains social functioning.
He provides concrete examples of the kinds of changes the team hopes to improve and measure. These include increased ability to make eye contact, better understanding of nonverbal cues such as recognising whether someone looks happy or sad, and a greater desire for social engagement rather than remaining absorbed in isolated interests.
He is careful to distinguish social communication from language mechanics. The goal is not to build vocabulary or general language skill. Instead, it is to improve the social use of communication, focusing on how a person connects, reads others, and participates interpersonally.
He also draws explicit boundaries around what L-179 is not intended to treat. It does not target common co-occurring challenges that are not required for an autism diagnosis. These include irritability, gastrointestinal problems, hyperactivity, and anxiety. Those are important issues, but they are not the focus of this program.
Finally, he emphasises realism. L-179 is not a cure, and it is not expected to work for everyone. He attributes this to the underlying biological heterogeneity of autism. He compares the present state of autism biology to how cancer was viewed decades ago, arguing that autism may represent many distinct molecular conditions. In his framing, a universal cure would need identifying each person’s specific molecular pathology. However, meaningful symptom-based treatments can still get developed for subsets of the population.
He reiterates an approximate target impact range of 25 to 30 percent. If L-179 proves effective, he believes it could stimulate additional industry efforts and expand future options for families.
Expected Outcomes and Patient Response
Dr. Megerian returns repeatedly to expectation-setting. L-179 is not expected to benefit every patient. The estimated responder subset is 25 to 30 percent. He explains this estimate in the context of autism’s heterogeneity, describing autism as potentially a collection of hundreds of rare diseases with different molecular drivers. It is an analogy he again ties to cancer research history.
He contrasts L-179’s observed effects with the uncertainty many families experience in other interventions. Parents may try approaches such as gluten-free diets or leucovorin and hope they are helping, but often do not see dramatic, immediate changes. Improvements observed over one to three years can be difficult to attribute confidently because maturation, school, and development can also produce change.
Against that backdrop, he shares specific trial-related and clinical observations described as unusually fast and functionally meaningful. Some parents reportedly recognised their child was on active medication rather than placebo within three days because of noticeable positive behavioural changes. Clinicians observed measurable changes as early as one month into treatment.
He provides examples of the types of functional gains reported. These include the ability to carry a tight conversation with a clear beginning, middle, and end. Increased social awareness, such as noticing a sibling’s new glasses or asking about a sibling’s plans for college. Reduced perseverative and obsessive questioning.
One highlighted anecdote involves identical twins in a randomized study. The parent reported that the twin receiving L-179 dramatically stopped the obsessive repetitive questioning within 3 days, whereas the twin on placebo continued to what he was used to doing.
He also describes a plausible mechanism for sustained functional gains as a behavioural-social cycle. If medication makes it easier to initiate engagement, the resulting positive responses from others may reinforce the behaviour and encourage the child to continue initiating interactions.
On durability, he reports that present data suggest children do not immediately regress when the medication is stopped. Some participants have maintained acquired skills or even continued to improve post discontinuation.
He also describes the evaluation approach designed to keep outcomes meaningful to families. The protocol enables the caregivers to choose specific target symptoms within the social communication or repetitive behaviour domains that are most prominent. This enables measurement of improvements that matter clinically for that particular child and family.
Clinical Trial Design and Patient Population
Dr. Megerian describes participant criteria and the rationale behind the program’s initial focus.
Studies to date have focused on adolescents ages 12 to 21. Adolescents were prioritised because placebo groups in that age bracket typically show less dramatic natural or therapy-driven developmental change than younger children. This makes it easier to detect whether improvements are attributable to the medication rather than rapid baseline developmental gains, such as those often seen when young children start early intervention or enter school.
Participants must have some verbal ability, defined specifically as the capacity to use small, non-scripted, non-echoed phrases of at least three words.
Inclusion criteria require that the child has been in stable therapy or schooling for at least six months prior to enrolment and must maintain that consistency throughout the study. This prevents confounding changes in outcomes due to major shifts in services.
Trial sites happen to be in diverse metropolitan areas. Dr. Megerian notes this supports representation across communities such as Asian, East Asian, Black, Middle Eastern, and Hispanic participants.
On safety and tolerability, he reports L-179 has been well tolerated. The most common side effects reported were transient: diarrhea, sleepiness, runny nose, and headache. He states none of these occurred significantly more often in the drug group than in placebo. In the most recent study, no participants discontinued due to adverse events attributed to the drug.
The team plans to investigate autonomic function markers, specifically pupillary response and heart rate variability, to see whether such abnormalities can predict who will respond to treatment.
Expansion plans include moving to younger children, including those as young as age 3. The plan is to run a Phase 2 study in younger children concurrently with Phase 3 for adolescents.
On international participation, he indicates there is no explicit restriction that would automatically bar international participants from flying in for visits. However, feasibility is currently limited by uncertainty around regulatory and legal implications of providing experimental medication in a context involving international travel and jurisdictional issues.
Implementation and Global Accessibility
Dr. Megerian frames L-179 as part of a multimodal care model. Medication is not intended as a replacement for educational or behavioural therapy. Rather, it is intended to be used alongside them just so that the gains are amplified.
He provides an analogy from cerebral palsy care. Using Botox to reduce spasticity can make physical therapy more effective. Similarly, facilitating social engagement may make behavioural and educational interventions more fruitful.
Adolescent clinical trials are scheduled to begin in 2027. The stated goal for regulatory approval is late 2029 or 2030 in the United States.
He notes the FDA may require clinical data across all age groups before granting final approval. However, they may show flexibility in the process depending on the strength of the results. This reinforces why age-range expansion is strategically important.
In context of the global rollout, he anticipates worldwide distribution will need to have strategic partnerships. The current organization is too small to implement international efforts alone. He underscores that global access will not happen immediately upon U.S. approval. There are many countries which typically require clinical studies conducted within their own borders before approving a medication. However, he expects momentum for international approval to strengthen once U.S. safety and efficacy are established and the drug looks clearly approvable.
On access and affordability, he expects the treatment would be widely covered by insurance and healthcare systems because there are currently no medical treatments available for core autism symptoms. For uninsured patients, the company anticipates creating access programs like those used by other pharmaceutical companies.
A Legacy in Progress
Dr. Thomas Megerian is not chasing a miracle. He is chasing progress. He is chasing the possibility that one day, a meaningful percentage of children having autism will get to have a medical option that targets the core symptoms of their condition. He is indeed chasing a legacy that outlasts his career.
As said before, he does not enjoy the spotlight. He would rather be in the clinic, with patients, doing the work. But he understands that the work requires resources. And resources require visibility. So, he participates. He speaks. He advocates.
The road to approval is long. Phase 3 is expensive. Regulatory pathways are complex. International access will take time. But for Dr. Megerian, the destination justifies the journey. If L-179 works, even for a subset of patients, it changes what is possible. It opens doors. It gives families something they have never had: a medical treatment designed for the core symptoms of autism.
That is not a cure. But it is a beginning. And for Dr. Megerian, a beginning is worth fighting for.
